Physiomics PLC
RVW1
Company Profile
Business description
Physiomics PLC is a United Kingdom-based firm that provides consulting services to biopharmaceutical companies and research institutes in the areas of outsourced modelling and simulation (quantitative pharmacology), biometrics, and data science (bioinformatics). Its business activities involve the use of industry-standard technologies and a proprietary technology platform called Virtual Tumour. The company has three service lines: Biometrics, Modelling and Simulation (Quantitative Pharmacology) and Personalised Medicine. It derives revenue from the UK, the European Union and Switzerland.
Contact
140 Eastern Avenue
Bee House, Milton Park
AbingdonOX14 4SB
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
10
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,391.10 | 14.40 | -0.15% |
| CAC 40 | 8,714.94 | 11.09 | -0.13% |
| DAX 40 | 26,391.42 | 67.54 | 0.26% |
| Dow JONES (US) | 53,791.85 | 184.13 | -0.34% |
| FTSE 100 | 10,844.19 | 18.31 | -0.17% |
| HKSE | 25,362.91 | 289.91 | -1.13% |
| NASDAQ | 26,445.45 | 159.91 | -0.60% |
| Nikkei 225 | 67,040.18 | 69.96 | 0.10% |
| NZX 50 Index | 13,779.05 | 81.61 | -0.59% |
| S&P 500 | 7,728.20 | 24.91 | -0.32% |
| S&P/ASX 200 | 9,193.00 | 18.60 | -0.20% |
| SSE Composite Index | 3,943.00 | 8.90 | 0.23% |